Tag: Bleeding Risk
-
Stopping DOACs After Successful AF Ablation: OCEAN Trial Feasible in Low-Risk Patients
Overview: Rethinking Anticoagulation After AF Ablation New data from the OCEAN trial suggest that stopping direct oral anticoagulants (DOACs) after a successful atrial fibrillation (AF) ablation may be feasible for low-risk patients. This challenges the long-standing practice of continuing anticoagulation based solely on prior AF history and CHADS2‑VASc scoring, and invites clinicians to re-evaluate individual…
-
Echocardiographic Hemodynamics Reveal DOAC-Specific Bleeding and Stroke Differences in Non-Valvular Afib
Background: DOACs, NVAF, and the bleeding-stroke balance Atrial fibrillation (AF) and atrial flutter (AFL) elevate stroke risk, driving the widespread use of oral anticoagulants. Direct oral anticoagulants (DOACs)—apixaban, rivaroxaban, dabigatran, and edoxaban—offer non-inferiority to warfarin with distinct bleeding profiles. In real-world practice, apixaban often shows the lowest overall bleeding, particularly GI bleeding, while rivaroxaban and…
-
Benefits of Shorter Dual Antiplatelet Therapy in Myocardial Infarction Patients
In the landscape of cardiovascular interventions, dual antiplatelet therapy (DAPT) has emerged as a cornerstone for patients who have experienced myocardial infarction (MI). Traditionally, a prolonged duration of DAPT, often reaching 12 months or more, was the norm. However, recent research has illuminated potential safety benefits associated with a shorter duration of treatment, specifically three…